Contraceptives are birth spacing products that aid in avoiding unplanned pregnancy. There are five widely used contraceptive methods, namely sterilization, hormonal method, barrier method, emergency contraception, and intrauterine method. Sterilization is the most common method implemented globally. While there are a plethora of female contraceptives available in the market, companies and a few University researchers are trying to introduce male contraceptive methods. Women contraceptive methods include vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid 60% of maternal deaths and 57% of child deaths worldwide, as opined by the World Health Organization (WHO) in 2014. Therefore, various family planning initiatives have been introduced by governmental and non-governmental agencies in order to create awareness about prevention of unplanned pregnancy.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/368

Market Dynamics

Companies present in the contraceptives market prefer marketing oral contraceptive pills to churn out considerable and constant revenues compared to one-time revenue generated through long-acting contraceptives. Moreover, there is heavy promotion of oral pills compared to the long acting contraceptives such as IUD, and implant. This has kept the consumers away from the real benefits of long acting contraceptives over the oral pills. This is the reason that oral pills dominate the U.S. contraceptive drugs and devices market. The oral pills market is projected to experience the entry of generics with patent expirations nearing in the forecast period.

However, demand for advanced contraceptive options such as IUD, injectables, implants and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods. Government promotes the use of IUD and implants i.e. long-acting contraceptives for better therapeutic effect and safety. Also, reimbursement schemes are made attractive for consumers to opt for these contraceptive methods.

Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Reckitt Benckiser Plc, Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Cooper Surgical, Inc., Allergan plc, Cipla Limited, and Merck & Co. Inc.

Detailed Segmentation:

U.S. Contraceptives Drugs And Devices Market, By Product Type:
Contraceptive Drugs
Oral Contraceptive Pills
Contraceptive Injectables
Topical Contraceptives
Contraceptive Devices
Male Contraceptive Devices
Condoms
Female Contraceptive Devices
Female Condoms
Contraceptive Diaphragms
Contraceptive Sponges
Contraceptive Vaginal Rings
Intrauterine Devices
Hormonal
Copper-T
Subdermal Contraceptive Implants
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Church & Dwight Co. Inc.
Reckitt Benckiser Plc
Pfizer, Inc.
Bayer AG
Mayer Laboratories, Inc.
The Female Health Company
Cooper Surgical, Inc.
Allergan Plc
Cipla Limited
Merck & Co. Inc.

Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market

Private companies have high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories and Cipla Limited are at pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills owing to extensive promotion activities to market these products.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/368

Favorable reimbursement scenario increasing adoption of contraceptives among low and middle-income population

Long-acting reversible contraceptives (LARC) are given complete insurance coverage by the U.S. Affordable Care Act. However, oral pills that generate sustainable revenue are of interest to market players. The availability of products and its cost in different sections of the society are affected due to public-private interest disparity.

Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

Insurance coverage for devices also varies from state to state in the U.S. Few states have low Medicaid reimbursement rates than the cost of the device, while few states provide reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates disparity in demand for certain contraceptives across regions in the U.S. Efforts to standardize the rule all over the country is expected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]